Europe
As we head into cold and flu season, the question arises: Can you get COVID-19 and the flu at the same time?
It’s entirely possible that what we will be seeing most from the U.S. Food and Drug Administration for the month of September is related to treatments and vaccines for COVID-19.
Treatments for COVID-19 may be focusing on at the wrong elements of the disease, according to physicians analyzing results from Bergamo, Italy, the epicenter of the pandemic in Europe.
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.
Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.
Biospace recently analyzed key emerging cell and gene therapy companies to get a handle on how this evolving science is beginning to make its way from research into clinical applications.
PRESS RELEASES